January 2019

Value-Based Agreements Take Center Stage at COA Summit

January 09, 2019

Clinical Articles

Pressure on regulators to reduce healthcare costs could be a response to the estimated $1 trillion in US expenditures from poor care coordination, administrative burdens, and fraud, said Jeff Mortier, partner at Farragut Partners, during the Community Oncology Alliance Payer Exchange Summit.

Does the Cost Outweigh the Benefit for CAR T-Cell Therapy?

January 09, 2019

Clinical Articles

The FDA-approved CAR T-cell therapies have instituted a new era of effective cancer therapies for patients and are the most expensive treatments to date. Now, physicians are faced with financial implications before introducing these novel agents into clinical practice.

FDA Advances the Use of Metastasis-Free Survival as an Endpoint in nmCRPC

January 10, 2019

Clinical Articles

In November 2018, the FDA issued a draft guidance recommending metastasis-free survival as an endpoint in drug trials for nonmetastatic castration-resistant prostate cancer, suggesting a major change in expectations for treatment of this tumor type.

Adjustable Predictors of ET Use in Black Women Could Improve Adherence

January 16, 2019

Clinical Articles

Nonadherence to endocrine therapy may explain why black women with hormone receptor–positive breast cancer have higher mortality rates than white women, despite historically lower incidence rates.

Broad-Panel NGS Benefits Metastatic NSCLC

January 11, 2019

Clinical Articles

Increasing clinical relevance of less common gene signatures and alterations is leading to a benefit from broad-panel next-generation sequencing testing for patients with metastatic non–small cell lung cancer, according to an expert at Memorial Sloan Kettering Cancer Center.